OncoMatch/Clinical Trials/NCT05730816
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Is NCT05730816 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Magnesium sulfate and Normal Saline for mesothelioma.
Treatment: Magnesium sulfate · Normal Saline — In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Mesothelioma
Lab requirements
Kidney function
eGFR <45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy [excluded]
Cardiac function
Sinus bradycardia (HR <55 bpm on any ECG in preceding 6 months) [excluded]; High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker [excluded]
eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months. High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05730816 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages